ADMA Biologics (NASDAQ:ADMA) Stock Price Up 3.5%

ADMA Biologics, Inc. (NASDAQ:ADMA - Get Free Report) shot up 3.5% during mid-day trading on Tuesday . The stock traded as high as $6.19 and last traded at $6.19. 862,242 shares were traded during mid-day trading, a decline of 67% from the average session volume of 2,645,077 shares. The stock had previously closed at $5.98.

Analyst Ratings Changes

Several research firms have recently issued reports on ADMA. Cantor Fitzgerald upped their target price on shares of ADMA Biologics from $6.50 to $8.00 and gave the stock an "overweight" rating in a research note on Thursday, February 29th. Mizuho increased their price target on shares of ADMA Biologics from $9.00 to $10.00 and gave the company a "buy" rating in a research report on Friday, March 1st. Finally, HC Wainwright restated a "buy" rating and set a $7.50 price target (up previously from $6.00) on shares of ADMA Biologics in a research report on Tuesday, March 26th. One equities research analyst has rated the stock with a hold rating, three have given a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat.com, ADMA Biologics currently has an average rating of "Buy" and an average price target of $7.88.

ADMA Biologics Price Performance

The stock has a market cap of $1.41 billion, a P/E ratio of -47.62 and a beta of 0.46. The company has a quick ratio of 1.69, a current ratio of 5.16 and a debt-to-equity ratio of 1.04. The business's 50-day simple moving average is $5.88 and its two-hundred day simple moving average is $4.71.

ADMA Biologics (NASDAQ:ADMA - Get Free Report) last issued its quarterly earnings results on Wednesday, February 28th. The biotechnology company reported $0.04 EPS for the quarter, beating analysts' consensus estimates of $0.02 by $0.02. ADMA Biologics had a negative net margin of 10.94% and a positive return on equity of 0.49%. The business had revenue of $73.90 million for the quarter, compared to analysts' expectations of $73.50 million. Sell-side analysts expect that ADMA Biologics, Inc. will post 0.3 EPS for the current year.

Insider Transactions at ADMA Biologics

In related news, Director Steve Elms sold 49,887 shares of the company's stock in a transaction dated Monday, March 18th. The shares were sold at an average price of $6.01, for a total value of $299,820.87. Following the transaction, the director now owns 2,527,500 shares in the company, valued at approximately $15,190,275. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. Insiders have sold 639,895 shares of company stock valued at $3,927,169 in the last three months. 5.90% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On ADMA Biologics

Hedge funds and other institutional investors have recently made changes to their positions in the business. Virtu Financial LLC purchased a new stake in ADMA Biologics in the 2nd quarter worth approximately $34,000. Price T Rowe Associates Inc. MD bought a new stake in ADMA Biologics in the second quarter worth $35,000. Envestnet Asset Management Inc. bought a new stake in ADMA Biologics in the first quarter worth $35,000. Stephens Consulting LLC bought a new stake in shares of ADMA Biologics during the third quarter worth $36,000. Finally, Cerity Partners LLC bought a new stake in shares of ADMA Biologics during the second quarter worth $37,000. Hedge funds and other institutional investors own 75.68% of the company's stock.

About ADMA Biologics

ADMA Biologics, Inc, a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B.